Josephine van Dongen

8 Summary and general discussion 203 54. Kandasamy R, Voysey M, McQuaid F, et al. Non-specific immunological effects of selected routine childhood immunisations: Systematic review. BMJ . 2016;355. doi:10.1136/bmj. i5225 55. Higgins JPT, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mor tality: Systematic review. BMJ. 2016;355. doi:10.1136/bmj.i5170 56. Tešović G. Childhood vaccinations in Croatia. Period Biol . 2012;114(2):149-166. 57. ECDC. Rotavirus infection: Recommended vaccination schedule. ECDC . Published 2021. Accessed February 24, 2021. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ ByDisease?SelectedDiseaseId=32&SelectedCountryIdByDisease=-1 58. Bonaldo G, Noseda R, Ceschi A,Vaccheri A, Motola D. Evaluation of the safety profile of rotavirus vaccines: a pharmacovigilance analysis on American and European data. Sci Rep. 2020;10(1):1-9. doi:10.1038/s41598-020-70653-3 59. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, Reactogenicity and Immunogenicity of the Human Rotavirus Vaccine in Preterm European Infants: A Randomized Phase IIIb Study. Pediatr Infect Dis J. 2012;31(5). doi:10.1097/INF.0b013e3182490a2c 60. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassor tant Rotavirus Vaccine in Healthy Premature Infants. Pediatr Infect Dis J. 2007;26(12):1099-1104. doi:10.1097/INF.0b013e31814521cb 61. Javid PJ, Sanchez SE, Jacob S, McNeal MM, Horslen SP, Englund JA. The safety and immunogenicity of rotavirus vaccination in infants with intestinal failure. J Pediatric Infect Dis Soc. Published online 2014. doi:10.1093/jpids/pit060 62. Fang AYW, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional shor t gut syndrome. J Paediatr Child Health. 2012;48(6):512-516. doi:10.1111/j.1440-1754.2011.02227.x 63. Rosettie KL, Vos T, Mokdad AH, et al. Indirect Rotavirus Vaccine Effectiveness for the Prevention of Rotavirus Hospitalization: A Systematic Review and Meta-Analysis. Am J Trop Med Hyg . Published online 2017. doi:10.4269/ajtmh.17-0705 64. Zlamy M, Kofler S, Or th D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis . 2013;13(1). doi:10.1186/1471-2334-13-112 65. Bányai K, László B, Duque J, et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: Insights for understanding the impact of rotavirus vaccination programs. Vaccine . 2012;30(SUPPL. 1):122-130. doi:10.1016/j. vaccine.2011.09.111 66. Harris VC, Haak BW, Handley SA, et al. Effect of Antibiotic-Mediated Microbiome Modulation on Rotavirus Vaccine Immunogenicity: A Human, Randomized-Control Proof-of- Concept Trial. Cell Host Microbe. 2018;24(2):197-207.e4. doi:10.1016/j.chom.2018.07.005 67. Harris V, Ali A, Fuentes S, et al. Rotavirus Vaccine Response Correlates with the Infant Gut Microbiota Composition in Pakistan. Gut Microbes . Published online 2017. doi:10.1080/19 490976.2017.1376162 68. Harris VC. The Significance of the Intestinal Microbiome for Vaccinology: From Correlations to Therapeutic Applications. Drugs . Published online 2018. doi:10.1007/s40265- 018-0941-3 69. Harris VC, Armah G, Fuentes S, et al. Significant Correlation Between the Infant Gut Microbiome and Rotavirus Vaccine Response in Rural Ghana. J Infect Dis . 2017;215(1):34-41. doi:10.1093/infdis/jiw518